NASDAQ:SGMT Sagimet Biosciences (SGMT) Stock Price, News & Analysis $5.42 -0.47 (-7.98%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$5.32▼$6.0050-Day Range$2.23▼$6.2052-Week Range$2.13▼$18.33Volume153,445 shsAverage Volume119,210 shsMarket Capitalization$115.88 millionP/E RatioN/ADividend YieldN/APrice Target$43.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Sagimet Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside705.7% Upside$43.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingAcquiring Shares$1,386 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($20.25) to ($1.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector604th out of 950 stocksPharmaceutical Preparations Industry293rd out of 442 stocks 3.5 Analyst's Opinion Consensus RatingSagimet Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.67, Sagimet Biosciences has a forecasted upside of 705.7% from its current price of $5.42.Amount of Analyst CoverageSagimet Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SGMT. Previous Next 0.0 Dividend Strength Dividend YieldSagimet Biosciences does not currently pay a dividend.Dividend GrowthSagimet Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGMT. Previous Next 2.7 News and Social Media Coverage News SentimentSagimet Biosciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sagimet Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SGMT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sagimet Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sagimet Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,386.00 in company stock and sold $0.00 in company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sagimet Biosciences are expected to grow in the coming year, from ($20.25) to ($1.71) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Sagimet Biosciences Stock (NASDAQ:SGMT)Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Read More SGMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGMT Stock News HeadlinesDecember 27, 2023 | americanbankingnews.comSagimet Biosciences (NASDAQ:SGMT) Trading Up 6.5%December 4, 2023 | finance.yahoo.comSagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst ClinicDecember 31, 2023 | MarketBeat Internal (Ad)Claim Your $300 MarketBeat Account CreditClick the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)November 28, 2023 | finance.yahoo.comSagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development SummitNovember 22, 2023 | finance.yahoo.comSagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare ConferenceNovember 18, 2023 | markets.businessinsider.comSagimet Biosciences: Promising Financial Outlook and FASN Inhibitor Trial Progress Bolster Buy RatingNovember 13, 2023 | msn.comSagimet Biosciences GAAP EPS of -$0.35, revenue of $2MNovember 13, 2023 | finance.yahoo.comSagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesDecember 31, 2023 | MarketBeat Internal (Ad)Claim Your $300 MarketBeat Account CreditClick the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)November 10, 2023 | finance.yahoo.comSagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023October 24, 2023 | finance.yahoo.comSagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023October 18, 2023 | finance.yahoo.comSagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor ConferenceSeptember 29, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Sagimet Biosciences, Inc. Class A (SGMT)September 27, 2023 | seekingalpha.comSagimet Biosciences: Recent IPO With Emerging Positive Data In NASHSeptember 27, 2023 | finance.yahoo.comSagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent GlioblastomaAugust 25, 2023 | finance.yahoo.comSagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesAugust 16, 2023 | finance.yahoo.comSagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public OfferingAugust 14, 2023 | finance.yahoo.comSagimet Biosciences Announces Pricing of Upsized Initial Public OfferingAugust 14, 2023 | finance.yahoo.comSagimet Biosciences Announces Leadership ChangesSee More Headlines Receive SGMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sagimet Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SGMT CUSIPN/A CIK1400118 Websagimet.com Phone650-561-8600FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$43.67 High Stock Price Target$67.00 Low Stock Price Target$31.00 Potential Upside/Downside+705.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio20.36 Quick Ratio20.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares21,380,000Free FloatN/AMarket Cap$115.88 million OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. George W. Kemble Ph.D. (Age 62)Executive Chairman of the Board Comp: $444.86kMr. David A. Happel (Age 61)CEO, President & Director Comp: $309.42kDr. Eduardo Bruno Martins DPhil (Age 60)M.D., Ph.D., Chief Medical Officer Comp: $536.83kMr. Urs Greber Ph.D.Co-FounderDr. Lucas Pelkmans Ph.D.Co-FounderMr. Anthony M. Rimac CPA (Age 59)CPA, CFO & Principal Accounting Officer Ms. Elizabeth Rozek J.D. (Age 52)General Counsel & Chief Compliance Officer Dr. Marie O'Farrell Ph.D.Senior Vice President of Research & DevelopmentMore ExecutivesKey CompetitorsAbeona TherapeuticsNASDAQ:ABEOEmergent BioSolutionsNYSE:EBSCarisma TherapeuticsNASDAQ:CARMCue BiopharmaNASDAQ:CUEIO BiotechNASDAQ:IOBTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 246,018 shares on 12/18/2023Ownership: 1.151%David HappelBought 590 shares on 11/16/2023Total: $1,386.50 ($2.35/share)Rock Springs Capital Management LPBought 738,355 shares on 11/15/2023Ownership: 3.458%RTW Investments LPBought 400,277 shares on 11/15/2023Ownership: 1.875%Dumac Inc.Bought 204,123 shares on 11/14/2023Ownership: 0.956%View All Insider TransactionsView All Institutional Transactions SGMT Stock Analysis - Frequently Asked Questions Should I buy or sell Sagimet Biosciences stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sagimet Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SGMT shares. View SGMT analyst ratings or view top-rated stocks. What is Sagimet Biosciences' stock price target for 2024? 4 Wall Street research analysts have issued 12-month price objectives for Sagimet Biosciences' shares. Their SGMT share price targets range from $31.00 to $67.00. On average, they anticipate the company's stock price to reach $43.67 in the next year. This suggests a possible upside of 705.7% from the stock's current price. View analysts price targets for SGMT or view top-rated stocks among Wall Street analysts. How have SGMT shares performed in 2023? Sagimet Biosciences' stock was trading at $15.95 on January 1st, 2023. Since then, SGMT shares have decreased by 66.0% and is now trading at $5.42. View the best growth stocks for 2023 here. When is Sagimet Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our SGMT earnings forecast. How were Sagimet Biosciences' earnings last quarter? Sagimet Biosciences Inc. (NASDAQ:SGMT) announced its earnings results on Monday, November, 13th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.67. The company earned $2 million during the quarter. When did Sagimet Biosciences IPO? (SGMT) raised $85 million in an initial public offering (IPO) on Friday, July 14th 2023. The company issued 5,312,500 shares at a price of $16.00 per share. When does Sagimet Biosciences' lock-up period expire? Sagimet Biosciences' lock-up period expires on Wednesday, January 10th. Sagimet Biosciences had issued 5,312,500 shares in its IPO on July 14th. The total size of the offering was $85,000,000 based on an initial share price of $16.00. After the expiration of Sagimet Biosciences' lock-up period, major shareholders and company insiders will be able to sell their shares of the company. How do I buy shares of Sagimet Biosciences? Shares of SGMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SGMT) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.